Novo Nordisk A/S (NVO) News Today

Novo Nordisk A/S (NYSE:NVO) shares are trading higher today, driven by a mix of positive regulatory approvals and commercial initiatives that bolster its blockbuster GLP-1 franchise, even as ongoing securities-fraud lawsuits present a potential headwind.

• Positive Sentiment: Expanded access to Ozempic—Novo Nordisk and partners (including GoodRx) are now offering the diabetes drug at $499/month to cash-paying, uninsured U.S. patients via multiple channels, aiming to widen the prescription base and drive volume. Novo Nordisk halves Ozempic price to $499 for US patients
• Positive Sentiment: Wegovy secures U.S. approval for liver disease (MASH)—the first GLP-1 therapy authorized for metabolic dysfunction-associated steatohepatitis, expanding the drug’s addressable market and triggering a ~4–5% premarket boost. Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
• Positive Sentiment: Robust sales growth—company-reported revenue rose 18% year-over-year, reflecting strong demand for semaglutide products and supporting confidence in full-year targets. NVO Reports 18% Sales Growth Amid Adjusted Outlook
• Neutral Sentiment: TD Cowen trims price target from $105 to $70 but keeps a “buy” rating, implying roughly 28% upside from current levels. Novo Nordisk price target lowered by TD Cowen
• Neutral Sentiment: Featured as a “promising growth stock” by MarketBeat, highlighting continued investor interest in Novo Nordisk’s pipeline and international expansion. Promising Growth Stocks To Research – August 18th
• Negative Sentiment: Heightened legal risk—a slew of class action notices from law firms (Levi & Korsinsky, Glancy Prongay & Murray, Bronstein Gewirtz & Grossman, etc.) warns investors about pending securities-fraud lawsuits tied to alleged misstatements in the May–July class period. Class Action Reminder by Levi & Korsinsky

While the class-action overhang warrants caution, investors have rewarded Novo Nordisk’s aggressive pricing strategy and regulatory wins for Ozempic and Wegovy, underpinning today’s upward move in NVO stock.